Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysis: Film-Maker Fujifilm To Enter Japan Drug Business with Toyama Chemical Acquisition

This article was originally published in PharmAsia News

Executive Summary

Fujifilm Holdings' bid to buy Toyama Chemical signals a move by companies with technologies beneficial to drug making to enter the pharmaceutical market. Ajinomoto, in the seasoning and food business, relies on fermentation technologies for its amino acid-based drugs, and Toray Industries applies biotechnology and nanotechnology to help develop drugs with long-lasting effects. Japan Pharmaceutical Manufacturers Association President Hatsuo Aoki said his industry expects to see an increase in mergers and acquisitions centered on certain technologies rather than company size. (Click here for more - a subscription may be required

You may also be interested in...



Fujifilm’s Tender Offer for Toyama Chemical Begins (Part 1 Of 2)

TOKYO - Fujifilm Holding's tender offer for Japanese pharma Toyama Chemical started as scheduled on Feb. 19 and will last for one month. In a move that took many in the business industry by surprise, the top global photographic and imaging company declared its intent to move into the pharmaceutical business in a joint announcement with Toyama Chemical and Taisho Pharmaceutical, the top over-the-counter drug company in Japan and major shareholder of Toyama Chemical

Taisho To Enter Lactic Acid Market With Biofermin Acquisition

Tokyo-based Taisho Pharmaceutical will take its first steps into the lactic acid bacteria drugs market following its proposed acquisition of Kobe, Japan-based Biofermin Pharmaceutical, approved by the latter's board Feb. 12

Radical Shake-Up In Store For Entire EU Pharma Legislation

The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel